Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

Resmetirom (MGL‐3196), a selective thyroid hormone receptor‐β agonist, was evaluated in a 36‐week paired liver biopsy study (NCT02912260) in adults with biopsy‐confirmed nonalcoholic steatohepatitis (NASH). The primary endpoint was relative liver fat reduction as assessed by MRI–proton density fat f...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Stephen A., Bashir, Mustafa, Moussa, Sam E., McCarty, Kevin, Pablo Frias, Juan, Taub, Rebecca, Alkhouri, Naim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034581/
https://www.ncbi.nlm.nih.gov/pubmed/33860116
http://dx.doi.org/10.1002/hep4.1657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034581/
https://www.ncbi.nlm.nih.gov/pubmed/33860116
http://dx.doi.org/10.1002/hep4.1657

Ejemplares similares